Generation of induced human thymic epithelial cells and its application in cell-based immunotherapies

Inventors

Weinacht, Katja G. • Gai, Hui

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Assignees

Leland Stanford Junior University

Stanford University

Todd Coleman is an associate professor of bioengineering at Stanford University. His research combines applied probability, physiology, and bioelectronics to develop methods and devices for monitoring and modulating nervous-system and other physiological activity, including brain and visceral-organ signals.

Publication Number

US-12767929-B2

Patent

Publication Date

2026-10-20

Expiration Date


Abstract

Methods of differentiating pluripotent stem cells into thymic epithelial progenitor cells are provided.

Core Innovation

The invention describes a staged human-cell differentiation platform that links definitive endoderm or anterior foregut cells to bipotent PPEIII cells, ventral PPEIII cells, and thymic epithelial progenitor cells. The described cell stages are characterized by specified markers and lineage potential: the bipotent cells can form thymus and parathyroid epithelial lineages, while the ventral PPEIII cells can further develop into thymic epithelial progenitor cells. [procedural detail omitted for safety]

The partial content identifies thymic reconstitution, immune reconstitution after hematopoietic stem cell transplantation, tolerance induction, and other applications involving impaired thymic function as intended uses. The background section is not included in the supplied content, so the problem being solved is not explicitly described there. The reported figures describe stage-specific marker changes and lineage potential, without establishing an additional stated problem.

Claims Coverage

The claims cover three inventive features corresponding to three successive differentiation stages: formation of bipotent PPEIII cells, formation of ventral PPEIII cells, and formation of thymic epithelial progenitor cells. [procedural detail omitted for safety]

Bipotent PPEIII cell differentiation

Claim 1 covers differentiation of a definitive endoderm or anterior foregut cell into a HOXA3+, TBX1+/high bipotent PPEIII cell committed to PPEIII and capable of further differentiation into thymus and parathyroid epithelial lineages. [procedural detail omitted for safety]

Ventral PPEIII cell differentiation

Claim 12 covers differentiation of a HOXA3+, TBX1+/high bipotent PPEIII cell into a TBX1dim, PAX1+, PAX9+, FOXG1+ ventral PPEIII cell that can further differentiate into thymic epithelial progenitor cells. [procedural detail omitted for safety]

Thymic epithelial progenitor cell differentiation

Claim 14 covers differentiation of a TBX1dim, PAX1+, PAX9+, FOXG1+ ventral PPEIII cell into a FOXN1+, PSMB11+, EPCAM+ thymic epithelial progenitor cell. [procedural detail omitted for safety]

Together, the claims cover successive formation of bipotent PPEIII cells, ventral PPEIII cells, and thymic epithelial progenitor cells.

Stated Advantages

Not explicitly described in patent.

Documented Applications

Thymic reconstitution and immune reconstitution after hematopoietic stem cell transplantation.

Tolerance induction.

Other applications involving impaired thymic function.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.